EQL Pharma AB (publ)

OM:EQL Stock Report

Market Cap: SEK 2.4b

EQL Pharma Management

Management criteria checks 3/4

EQL Pharma's CEO is Axel Schorling, appointed in Aug 2022, has a tenure of 2.75 years. total yearly compensation is SEK2.26M, comprised of 72.6% salary and 27.4% bonuses, including company stock and options. directly owns 1.08% of the company’s shares, worth SEK25.80M. The average tenure of the management team and the board of directors is 2.8 years and 5.3 years respectively.

Key information

Axel Schorling

Chief executive officer

SEK 2.3m

Total compensation

CEO salary percentage72.63%
CEO tenure2.8yrs
CEO ownership1.1%
Management average tenure2.8yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

EQL Pharma's (STO:EQL) Earnings Are Of Questionable Quality

May 16
EQL Pharma's (STO:EQL) Earnings Are Of Questionable Quality
author-image

Pipeline Launches And Global Expansion Will Drive Future Success

Strategic expansions and acquisitions, including Medilink and non-European market entry, are poised to drive significant revenue and profitability growth.

Here's Why EQL Pharma (STO:EQL) Can Manage Its Debt Responsibly

Mar 12
Here's Why EQL Pharma (STO:EQL) Can Manage Its Debt Responsibly
author-image

EQL Pharma aiming for 19% Revenue Growth in 5 Years

Recurring Cash Flow: EQL’s core generic product delivers near‐“infinite” cash flow, thanks to its essential role in healthcare. 

The Trend Of High Returns At EQL Pharma (STO:EQL) Has Us Very Interested

Jan 27
The Trend Of High Returns At EQL Pharma (STO:EQL) Has Us Very Interested

EQL Pharma AB (publ)'s (STO:EQL) P/E Is Still On The Mark Following 37% Share Price Bounce

Dec 14
EQL Pharma AB (publ)'s (STO:EQL) P/E Is Still On The Mark Following 37% Share Price Bounce

Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?

Nov 27
Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Oct 29
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28
With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24
EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19
EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29
Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29
Is EQL Pharma (NGM:EQL) Using Too Much Debt?

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07
EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16
If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03
Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16
What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11
What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22
EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

CEO Compensation Analysis

How has Axel Schorling's remuneration changed compared to EQL Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

SEK 43m

Dec 31 2024n/an/a

SEK 35m

Sep 30 2024n/an/a

SEK 31m

Jun 30 2024n/an/a

SEK 26m

Mar 31 2024SEK 2mSEK 2m

SEK 23m

Compensation vs Market: Axel's total compensation ($USD233.55K) is below average for companies of similar size in the Swedish market ($USD510.67K).

Compensation vs Earnings: Insufficient data to compare Axel's compensation with company performance.

CEO

Axel Schorling (38 yo)

2.8yrs

Tenure

SEK 2,262,000

Compensation

Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...

Leadership Team

NamePositionTenureCompensationOwnership
Christer Fahraeus
Founder & Chairman19.3yrsSEK 250.00kno data
Axel Schorling
President & CEO2.8yrsSEK 2.26m1.08%
SEK 25.8m
Anna Jonsson
Chief Financial Officer3.4yrsno datano data
Martin Kristofferson
Chief Operating Officer2.8yrsno data0.070%
SEK 1.7m
Alexander Brising
Chief Commercial Officerno datano datano data
Carl Lindgren
Chief Business Development Officer2.2yrsno datano data
Henrik Nilsson
Chief Quality Officerless than a yearno datano data

2.8yrs

Average Tenure

54yo

Average Age

Experienced Management: EQL's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christer Fahraeus
Founder & Chairman19.3yrsSEK 250.00kno data
Linda Neckmar
Independent Director5.3yrsSEK 100.00kno data
Anders Mansson
Independent Director6.8yrsSEK 100.00kno data
Per Svangren
Independent Director4.3yrsSEK 100.00kno data
Per Ollermark
Independent Director4.3yrsSEK 100.00kno data

5.3yrs

Average Tenure

57yo

Average Age

Experienced Board: EQL's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 21:44
End of Day Share Price 2025/05/19 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

EQL Pharma AB (publ) is covered by 1 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdCarnegie Commissioned Research